Procarbazine
- Atc Codes:L01XB01
- CAS Codes:366-70-1#671-16-9
- PHARMGKB ID:366-70-1#671-16-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
France: Natulan; Germany: Natulan; Greece: Natulan; Italy: Natulan; Luxembourg: Natulan; Netherlands: Natulan; Spain: Natulan; Sweden: Natulan; UK: Procarbazine.
North America
Canada: Matulane; USA: Matulane.
Asia
Japan: Natulan, Procarbazine.
Drug combinations
Chemistry
Procarbazine Hydrochloride: C~12~H~19~N~3~O HCl. Mw: 257.76. (1) Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-, monohydrochloride; (2) N-Isopropyl-α-(2-methylhydrazino)-p-toluamide monohydrochloride. CAS-366-70-1; CAS-671-16-9 (procarbazine)(1967).
Pharmacologic Category
Other Antineoplastic Agents; Methylhydrazines. (ATC-Code: L01XB01).
Mechanism of action
Precise mechanism(s) of action unknown. May inhibit protein, RNA, and DNA synthesis by inhibiting transmethylation of methyl groups of methionine into t-RNA. May damage DNA directly and suppress mitosis. Also has MAO-inhibiting properties.
Therapeutic use
Treatment of Hodgkin’s disease.
Pregnancy and lactiation implications
Animal studies demonstrated teratogenic effects. There are no adequate, well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant during treatment. Not recommended during lactation.
Unlabeled use
Treatment of non-Hodgkin’s lymphoma, brain tumors, melanoma, lung cancer, multiple myeloma.
Contraindications
Hypersensitivity to procarbazine or any component of the formulation. Pre-existing bone marrow aplasia. Ethanol ingestion. Pregnancy.
Warnings and precautions
Hazardous agent. Bone marrow suppression may occur 2-8 weeks after treatment initiation. Treatment should be withheld for CNS toxicity, diarrhea, hemorrhage, stomatitis or hypersensitivity. Ethanol consumption may cause disulfiram-like reaction (should be avoided). May cause hemolysis and/or presence of Heinz inclusion bodies in erythrocytes. May cause infertility. Possibly carcinogenic (acute leukemia and lung cancer reported following use). Use with caution in hepatic and renal impairment. Possesses MAO inhibitor activity and has potential for severe drug and food interactions.